Recent News from (OTC: BKIT)
| NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on June 16, 2017|
|Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: GBLX 7.60% – News: CEO’s interview published in an article GEVO 4.84% – News: Stockholders vote to clear way for Whitebox deb...|
| Date: June, 16 2017 13:00|
| NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on March 2, 2017|
|Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ALQA 27.11% – News: Presenting at Cowen and Company 37th Annual Health Care Conference on March 8 VBIO 19.65% – News: Develops propr...|
| Date: March, 02 2017 12:48|
| Blake Insomnia Therapeutics Inc. Closes Joint Venture with Sajo Consulting LLC|
|NEW YORK, Feb. 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce completion of a joint venture agreement for the development and commercialization of a series of oral drug products to aid in the treatment of insomnia. ...|
| Date: February, 24 2017 20:08|
| Blake Insomnia Therapeutics Inc. enters a joint development with Sajo Consulting LLC|
|NEW YORK, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce entry into a Letter of Intent to provide joint development and commercialization of Zleepax™, in combination with formulations to produce a series...|
| Date: February, 08 2017 16:54|
About Blake Insomnia Therapeutics, Inc. (OTC: BKIT)
Blake Insomnia Therapeutics, Inc. is a New York based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia. Our patent pending compound, Zleepax ZLX , has demonstrated efficacy without causing side effects which has been identified as the No. problem with current sleep medications.
- Birger Jan Olsen / CEO, CFO, President, Treasurer
- Founder and CEO Birger Jan Olsen is a seasoned executive, inventor and marketer who has spent over years working primarily in pharmaceuticals and medical devices. In addition to Blake Insomnia Therapeutics, Birger has founded some business, including the pioneering neuromarketing company Mindmetic and ProjektGruppen, a successful pharmafocused marketing agency. As an inventor, Birger developed Blake s patentpending ZLX sleep medicine compound, along with a patented method for automatically interpreting brain activity, a complianceboosting dosing device for osteoporosis patients, acquired by Roche Pharmaceuticals, and the widely used Globase automated marketing tool, acquired by AdPepper. Birger s careerlong focus on startups has given him a wealth of experience with earlystage business processes, including fundraising and early organizational development.
- Jillian Sidoti / Securities Counsel
Current Share Structure
- Market Cap: $2,053,842 - 03/16/2018
- Authorized: 100,000,000 - 03/01/2018
- Issue and Outstanding: 31,597,572 - 03/01/2018
- Float: 10,597,572 - 10/01/2016
Recent Filings from (OTC: BKIT)
Daily Technical Chart for (OTC: BKIT)
Stay tuned for daily updates and more on (OTC: BKIT)
It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter
More to come on (OTC: BKIT)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
The Subway Trader
Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BKIT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BKIT and does not buy, sell, or trade any shares of BKIT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/